Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free BRNS Stock Alerts

Barinthus Biotherapeutics (BRNS) Financials

Barinthus Biotherapeutics logo
$0.56 +0.01 (+1.44%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Barinthus Biotherapeutics

Annual Income Statements for Barinthus Biotherapeutics

This table shows Barinthus Biotherapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -18 -51 5.34 -73 -61 -66
Consolidated Net Income / (Loss)		 -18 -51 5.32 -73 -61 -66
Net Income / (Loss) Continuing Operations		 -18 -51 5.32 -73 -61 -66
Total Pre-Tax Income 		-18 -51 0.85 -77 -61 -67
Total Operating Income		 -20 -45 -4.04 -84 -68 -71
Total Gross Profit		 4.82 0.27 45 0.80 15 0.00
Total Revenue		 4.82 0.27 45 0.80 15 0.00
Operating Revenue		 4.82 0.27 45 0.80 15 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 22 45 49 85 83 71
Selling, General & Admin Expense		 10 25 6.39 40 30 41
Research & Development Expense		 11 20 42 45 42 26
Other Operating Expenses / (Income)		 - - - 0.00 -1.18 -0.51
Impairment Charge		 - - - 0.00 12 4.67
Total Other Income / (Expense), net		 -1.07 -5.92 4.89 7.39 6.74 3.92
Interest Expense		 3.60 16 0.02 0.03 0.05 0.05
Interest & Investment Income		 0.00 0.00 3.10 2.88 2.68 1.96
Other Income / (Expense), net		 2.53 11 1.81 4.54 4.12 2.02
Income Tax Expense		 0.10 -0.03 -4.47 -3.08 -0.04 -0.18
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.23 -0.25 -0.02 -0.10 -0.11 -0.03
Basic Earnings per Share		 ($2.24) ($1.96) $0.14 ($1.91) ($1.55) ($1.64)
Weighted Average Basic Shares Outstanding		 7.90M 25.89M 37.25M 38.39M 39.35M 40.53M
Diluted Earnings per Share		 ($2.24) ($1.96) $0.14 ($1.91) ($1.55) ($1.64)
Weighted Average Diluted Shares Outstanding		 7.90M 25.89M 38.17M 38.39M 39.35M 40.53M
Weighted Average Basic & Diluted Shares Outstanding		 - 37.19M 38.34M 38.92M 40.34M 40.85M

Quarterly Income Statements for Barinthus Biotherapeutics

This table shows Barinthus Biotherapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -14 -17 -15 -17 -8.11 -21 -20 -21 -15 -11 -5.53
Consolidated Net Income / (Loss)		 -14 -17 -16 -17 -8.13 -21 -20 -21 -15 -11 -5.53
Net Income / (Loss) Continuing Operations		 -14 -17 -16 -17 -8.13 -21 -20 -21 -15 -11 -5.53
Total Pre-Tax Income 		-15 -18 -16 -17 -8.13 -21 -20 -21 -15 -11 -5.55
Total Operating Income		 -16 -20 -17 -18 -9.38 -23 -21 -23 -15 -12 -6.08
Total Gross Profit		 0.00 - 0.00 0.00 15 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 15 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 16 20 17 18 24 23 21 23 15 12 6.08
Selling, General & Admin Expense		 0.96 14 5.99 7.20 13 3.06 13 15 5.17 7.64 2.53
Research & Development Expense		 15 6.37 11 12 11 8.31 8.29 7.95 5.39 3.93 3.59
Other Operating Expenses / (Income)		 0.00 - -0.21 -0.58 -0.21 -0.18 -0.33 -0.01 -0.16 -0.01 -0.05
Total Other Income / (Expense), net		 1.39 1.88 1.36 1.34 1.25 2.80 0.92 2.17 0.42 0.41 0.53
Interest Expense		 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01
Interest & Investment Income		 0.20 0.57 0.78 0.64 0.63 0.64 0.56 0.52 0.47 0.41 0.35
Other Income / (Expense), net		 1.20 1.31 0.59 0.71 0.63 2.18 0.38 1.66 -0.04 0.01 0.19
Income Tax Expense		 -0.60 -0.82 -0.04 -0.01 -0.00 0.00 -0.02 -0.03 -0.07 -0.06 -0.02
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.04 0.00 -0.03 -0.01 -0.02 -0.05 -0.01 -0.00 -0.01 -0.01 -0.00
Basic Earnings per Share		 ($0.37) ($0.44) ($0.40) ($0.43) ($0.21) ($0.51) ($0.49) ($0.52) ($0.36) ($0.27) ($0.14)
Weighted Average Basic Shares Outstanding		 38.53M 38.39M 38.77M 39.04M 39.42M 39.35M 40.27M 40.34M 40.66M 40.53M 40.85M
Diluted Earnings per Share		 ($0.37) ($0.44) ($0.40) ($0.43) ($0.21) ($0.51) ($0.49) ($0.52) ($0.36) ($0.27) ($0.14)
Weighted Average Diluted Shares Outstanding		 38.53M 38.39M 38.77M 39.04M 39.42M 39.35M 40.27M 40.34M 40.66M 40.53M 40.85M
Weighted Average Basic & Diluted Shares Outstanding		 38.57M 38.92M 39.03M 39.41M 40.23M 40.34M 40.34M 40.72M 40.83M 40.85M 40.85M

Annual Cash Flow Statements for Barinthus Biotherapeutics

This table details how cash moves in and out of Barinthus Biotherapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 30 177 -20 -52 -30 -41
Net Cash From Operating Activities		 -11 -33 -14 -51 -29 -48
Net Cash From Continuing Operating Activities		 -11 -33 -14 -51 -29 -48
Net Income / (Loss) Continuing Operations		 -18 -51 5.32 -73 -61 -66
Consolidated Net Income / (Loss)		 -18 -51 5.32 -73 -61 -66
Depreciation Expense		 0.21 0.60 4.32 5.43 5.80 5.85
Non-Cash Adjustments To Reconcile Net Income		 5.07 22 -13 14 21 20
Changes in Operating Assets and Liabilities, net		 1.63 -3.69 -11 3.28 5.77 -6.93
Net Cash From Investing Activities		 -0.29 -13 -5.75 -5.41 -0.89 0.42
Net Cash From Continuing Investing Activities		 -0.29 -13 -5.75 -5.41 -0.89 0.42
Purchase of Property, Plant & Equipment		 -0.29 -1.15 -6.14 -5.41 -0.89 -0.04
Sale of Property, Plant & Equipment		 - 0.00 0.39 - 0.00 0.45
Net Cash From Financing Activities		 41 223 0.33 1.87 2.16 0.00
Net Cash From Continuing Financing Activities		 41 223 0.33 1.87 2.16 0.00
Issuance of Common Equity		 0.00 103 0.48 2.04 2.16 0.00
Effect of Exchange Rate Changes		 - - 0.19 2.17 -2.02 7.01

Quarterly Cash Flow Statements for Barinthus Biotherapeutics

This table details how cash moves in and out of Barinthus Biotherapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -13 -18 -12 -12 -12 6.30 -12 -13 -12 -3.82 -4.66
Net Cash From Operating Activities		 -11 -20 -12 -12 -18 13 -15 -18 -11 -4.24 -3.37
Net Cash From Continuing Operating Activities		 -11 -20 -12 -12 -18 13 -15 -18 -11 -4.24 -3.37
Net Income / (Loss) Continuing Operations		 -14 -17 -16 -17 -8.13 -21 -20 -21 -15 -11 -5.53
Consolidated Net Income / (Loss)		 -14 -17 -16 -17 -8.13 -21 -20 -21 -15 -11 -5.53
Depreciation Expense		 1.47 1.44 1.43 1.47 1.48 1.43 2.03 2.00 0.90 0.91 0.86
Non-Cash Adjustments To Reconcile Net Income		 -1.35 1.63 0.63 2.69 -13 30 7.13 2.42 4.32 5.69 -1.12
Changes in Operating Assets and Liabilities, net		 2.79 -5.38 1.64 0.78 1.18 2.16 -4.41 -1.41 -1.37 0.26 2.43
Net Cash From Investing Activities		 -0.04 0.15 -0.31 -0.19 -0.11 -0.28 -0.01 -0.03 0.45 0.00 0.06
Net Cash From Continuing Investing Activities		 -0.04 0.15 -0.31 -0.19 -0.11 -0.28 -0.01 -0.03 0.45 0.00 0.06
Purchase of Property, Plant & Equipment		 -0.04 0.15 -0.31 -0.19 -0.11 -0.28 -0.01 -0.03 - - 0.00
Sale of Property, Plant & Equipment		 - - - - - - 0.00 - - 0.00 0.06
Net Cash From Financing Activities		 0.05 0.11 0.50 0.36 0.47 0.84 0.00 - - - 0.00
Net Cash From Continuing Financing Activities		 0.05 0.11 0.50 0.36 0.47 0.84 0.00 - - - 0.00
Issuance of Common Equity		 0.05 0.11 0.50 0.36 0.47 0.84 0.00 - - - 0.00
Effect of Exchange Rate Changes		 -1.54 1.12 -0.49 -0.36 - - 3.08 5.35 -1.84 0.42 -1.35

Annual Balance Sheets for Barinthus Biotherapeutics

This table presents Barinthus Biotherapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 51 281 270 215 160 98
Total Current Assets		 48 227 213 157 126 78
Cash & Equivalents		 43 214 194 142 111 70
Restricted Cash		 - - - 0.00 1.74 1.40
Prepaid Expenses		 1.41 6.46 8.27 9.91 6.20 4.83
Other Current Assets		 2.71 6.23 4.54 4.91 7.14 1.11
Plant, Property, & Equipment, net		 0.63 1.83 7.96 12 7.37 3.52
Total Noncurrent Assets		 2.14 52 49 46 27 17
Intangible Assets		 - 31 28 25 22 14
Other Noncurrent Operating Assets		 2.14 8.06 8.73 8.46 5.27 2.57
Total Liabilities & Shareholders' Equity		 51 281 270 215 160 98
Total Liabilities		 54 28 27 28 30 24
Total Current Liabilities		 7.64 11 12 13 16 10
Accounts Payable		 4.67 2.42 3.75 1.60 2.47 0.35
Accrued Expenses		 2.54 7.88 8.06 9.21 9.53 6.25
Current Deferred Revenue		 0.25 0.18 - 0.00 1.74 1.40
Other Current Liabilities		 0.19 0.52 0.43 1.79 1.92 2.02
Total Noncurrent Liabilities		 46 17 15 15 15 14
Noncurrent Deferred & Payable Income Tax Liabilities		 - 8.08 3.75 0.57 0.44 0.25
Other Noncurrent Operating Liabilities		 1.47 8.91 11 14 14 14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -37 253 243 187 130 74
Total Preferred & Common Equity		 -37 252 243 187 130 74
Total Common Equity		 -37 252 243 187 130 74
Common Stock		 22 369 380 387 393 394
Retained Earnings		 -58 -109 -103 -177 -238 -304
Accumulated Other Comprehensive Income / (Loss)		 -1.24 -8.49 -33 -23 -26 -16
Other Equity Adjustments		 - 0.09 0.09 0.09 0.09 0.09
Noncontrolling Interest		 0.39 0.44 0.31 0.21 0.11 0.08

Quarterly Balance Sheets for Barinthus Biotherapeutics

This table presents Barinthus Biotherapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 230 199 187 189 142 130 109 92
Total Current Assets		 171 143 132 135 110 100 87 73
Cash & Equivalents		 160 - - - 99 86 74 66
Restricted Cash		 - 130 118 106 1.46 1.53 1.40 1.33
Prepaid Expenses		 6.58 7.96 9.58 8.18 6.31 7.68 6.34 4.24
Other Current Assets		 4.17 5.20 4.52 20 3.00 4.54 4.63 1.23
Plant, Property, & Equipment, net		 12 12 11 11 6.20 4.51 4.52 3.27
Total Noncurrent Assets		 47 45 44 43 26 25 18 16
Intangible Assets		 26 24 24 23 21 20 15 14
Other Noncurrent Operating Assets		 8.53 8.29 8.17 8.37 4.76 4.27 2.99 2.54
Total Liabilities & Shareholders' Equity		 230 199 187 189 142 130 109 92
Total Liabilities		 34 27 30 29 26 27 25 26
Total Current Liabilities		 19 13 16 15 12 13 11 12
Accounts Payable		 5.15 1.16 2.56 3.08 1.36 1.80 0.70 0.99
Accrued Expenses		 12 8.33 10 7.97 7.20 7.36 6.68 8.69
Current Deferred Revenue		 - 1.43 0.84 2.04 1.46 1.53 1.40 0.32
Other Current Liabilities		 1.50 1.91 1.92 1.99 1.96 2.04 2.02 2.01
Total Noncurrent Liabilities		 16 15 14 14 14 14 14 14
Noncurrent Deferred & Payable Income Tax Liabilities		 1.52 0.54 0.49 0.46 0.42 0.39 0.32 0.24
Other Noncurrent Operating Liabilities		 14 14 14 14 14 14 14 13
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 196 172 157 159 116 102 85 66
Total Preferred & Common Equity		 195 172 157 159 115 102 84 66
Total Common Equity		 195 172 157 159 115 102 84 66
Common Stock		 386 389 390 392 394 394 393 395
Retained Earnings		 -159 -192 -209 -217 -257 -278 -293 -310
Accumulated Other Comprehensive Income / (Loss)		 -31 -25 -25 -16 -21 -13 -16 -19
Other Equity Adjustments		 0.09 0.09 0.09 0.09 0.09 0.09 0.09 0.09
Noncontrolling Interest		 0.21 0.18 0.17 0.17 0.10 0.10 0.10 0.08

Annual Metrics And Ratios for Barinthus Biotherapeutics

This table displays calculated financial ratios and metrics derived from Barinthus Biotherapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 34,852,426.00 37,296,515.00 38,565,272.00 40,228,456.00 40,830,353.00
DEI Adjusted Shares Outstanding		 0.00 34,852,426.00 37,296,515.00 38,565,272.00 40,228,456.00 40,830,353.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -1.46 0.14 -1.90 -1.52 -1.63
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% -94.44% 16,580.22% -98.21% 1,766.46% -100.00%
EBITDA Growth		 0.00% -96.91% 106.13% -3,639.59% 21.49% -8.00%
EBIT Growth		 0.00% -98.01% 93.56% -3,452.86% 19.55% -7.34%
NOPAT Growth		 0.00% -125.59% 20.09% -132.20% 19.00% -3.80%
Net Income Growth		 0.00% -185.02% 110.41% -1,480.32% 16.70% -8.62%
EPS Growth		 0.00% 12.50% 107.14% -1,464.29% 18.85% -5.81%
Operating Cash Flow Growth		 0.00% -195.46% 55.71% -252.89% 43.17% -65.79%
Free Cash Flow Firm Growth		 0.00% 0.00% 50.79% -54.68% 62.78% -67.05%
Invested Capital Growth		 0.00% 2,357.27% 26.25% -8.01% -60.51% -86.24%
Revenue Q/Q Growth		 0.00% -55.63% 16.83% -88.95% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -6.06% -83.29% 7.67% -4.59% 12.73%
EBIT Q/Q Growth		 0.00% -6.82% -124.73% 6.90% -4.14% 12.35%
NOPAT Q/Q Growth		 0.00% -18.42% -546.16% 5.81% -5.27% 14.35%
Net Income Q/Q Growth		 0.00% -10.00% -52.97% 5.01% -5.70% 12.49%
EPS Q/Q Growth		 0.00% 50.75% -90.07% 5.91% -4.73% 12.77%
Operating Cash Flow Q/Q Growth		 0.00% -10.42% -30.48% -19.36% 53.04% -56.53%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -19.03% -2.27% 67.74% -161.13%
Invested Capital Q/Q Growth		 0.00% 349.62% 10.82% 27.23% -66.76% -72.11%
Profitability Metrics		 - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin		 -359.03% -12,717.54% 4.67% -9,219.70% -387.81% 0.00%
Operating Margin		 -415.81% -16,873.51% -9.04% -10,463.09% -454.07% 0.00%
EBIT Margin		 -363.35% -12,942.16% -5.00% -9,896.63% -426.56% 0.00%
Profit (Net Income) Margin		 -371.98% -19,071.64% 11.90% -9,157.98% -408.73% 0.00%
Tax Burden Percent		 100.53% 99.95% 626.00% 95.98% 99.93% 99.74%
Interest Burden Percent		 101.83% 147.44% -38.05% 96.41% 95.89% 97.22%
Effective Tax Rate		 0.00% 0.00% -526.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -171.32% -57.83% -125.35% -151.91% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -153.00% -72.83% -116.61% -141.22% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 130.33% 59.98% 91.20% 113.33% 0.00%
Return on Equity (ROE)		 569.84% -40.99% 2.15% -34.15% -38.59% -65.02%
Cash Return on Invested Capital (CROIC)		 0.00% -186.30% -81.03% -117.00% -65.16% -337.98%
Operating Return on Assets (OROA)		 -34.57% -20.93% -0.81% -32.75% -34.07% 0.00%
Return on Assets (ROA)		 -35.39% -30.85% 1.93% -30.31% -32.65% 0.00%
Return on Common Equity (ROCE)		 6,754.66% -35.30% 2.14% -34.10% -38.55% -64.96%
Return on Equity Simple (ROE_SIMPLE)		 48.07% -20.27% 2.19% -39.32% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -14 -32 -25 -59 -48 -49
NOPAT Margin		 -291.06% -11,811.46% -56.59% -7,324.16% -317.85% 0.00%
Net Nonoperating Expense Percent (NNEP)		 272.02% -18.32% 15.00% -8.74% -10.69% -18.53%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -31.41% -36.56% -66.48%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 217.38% 9,372.39% 14.30% 4,967.83% 198.21% 0.00%
R&D to Revenue		 230.41% 7,601.12% 94.74% 5,595.26% 282.16% 0.00%
Operating Expenses to Revenue		 447.79% 16,973.51% 109.04% 10,563.09% 554.07% 0.00%
Earnings before Interest and Taxes (EBIT)		 -18 -35 -2.23 -79 -64 -69
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -17 -34 2.09 -74 -58 -63
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 1.54 0.36 0.76 0.37 0.39
Price to Tangible Book Value (P/TBV)		 0.00 1.86 0.43 0.95 0.45 0.48
Price to Revenue (P/Rev)		 22.92 1,444.82 1.96 177.44 3.25 0.00
Price to Earnings (P/E)		 0.00 0.00 16.41 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 6.09% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 4.49 0.00 0.01 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 30.30 648.33 0.00 0.53 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 -14.20 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 -14.20 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.46 -0.85 -0.82 -0.78 -0.80 -0.90
Leverage Ratio		 -16.10 1.33 1.11 1.13 1.18 1.26
Compound Leverage Factor		 -16.39 1.96 -0.42 1.09 1.13 1.23
Debt to Total Capital		 107.57% 0.06% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.06% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 107.57% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 82.20% 0.17% 0.13% 0.11% 0.08% 0.11%
Common Equity to Total Capital		 -89.77% 99.76% 99.87% 99.89% 99.92% 99.89%
Debt to EBITDA		 -2.58 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 -0.08 6.28 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -2.58 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -3.19 -0.01 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -0.10 6.76 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -3.19 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -0.46 8.23 2.44 1.54 -1.51 -5.09
Noncontrolling Interest Sharing Ratio		 -1,085.35% 13.87% 0.15% 0.12% 0.10% 0.09%
Liquidity Ratios		 - - - - - -
Current Ratio		 6.27 20.32 17.40 12.45 8.03 7.77
Quick Ratio		 5.73 19.19 16.36 11.28 7.07 7.03
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -72 -35 -55 -20 -34
Operating Cash Flow to CapEx		 -3,763.82% -2,843.19% -250.97% -940.79% -3,244.39% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 -4.38 -1,865.56 -1,958.17 -385.08 -668.50
Operating Cash Flow to Interest Expense		 -3.06 -1.98 -759.53 -1,818.75 -546.04 -940.76
Operating Cash Flow Less CapEx to Interest Expense		 -3.14 -2.05 -1,062.16 -2,012.07 -562.87 -932.61
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.10 0.00 0.16 0.00 0.08 0.00
Accounts Receivable Turnover		 9.31 1.00 15.24 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 7.66 0.22 9.14 0.08 1.56 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 39.22 366.36 23.95 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 39.22 366.36 23.95 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -1.71 39 49 45 18 2.44
Invested Capital Turnover		 -2.81 0.01 1.02 0.02 0.48 0.00
Increase / (Decrease) in Invested Capital		 0.00 40 10 -3.91 -27 -15
Enterprise Value (EV)		 146 174 -106 0.43 -64 -43
Market Capitalization		 111 387 88 142 49 29
Book Value per Share		 ($4.72) $7.23 $6.51 $4.84 $3.23 $1.82
Tangible Book Value per Share		 ($4.72) $5.97 $5.43 $3.88 $2.69 $1.47
Total Capital		 42 253 243 187 130 74
Total Debt		 45 0.16 0.00 0.00 0.00 0.00
Total Long-Term Debt		 45 0.00 0.00 0.00 0.00 0.00
Net Debt		 1.43 -214 -194 -142 -112 -72
Capital Expenditures (CapEx)		 0.29 1.15 5.75 5.41 0.89 -0.42
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.01 1.71 6.41 2.22 -2.32 -4.08
Debt-free Net Working Capital (DFNWC)		 40 216 201 144 110 68
Net Working Capital (NWC)		 40 216 201 144 110 68
Net Nonoperating Expense (NNE)		 3.90 19 -31 15 14 17
Net Nonoperating Obligations (NNO)		 1.43 -214 -194 -142 -112 -72
Total Depreciation and Amortization (D&A)		 0.21 0.60 4.32 5.43 5.80 5.85
Debt-free, Cash-free Net Working Capital to Revenue		 -62.35% 638.81% 14.35% 276.43% -15.47% 0.00%
Debt-free Net Working Capital to Revenue		 835.10% 80,509.70% 449.18% 17,993.39% 735.42% 0.00%
Net Working Capital to Revenue		 835.10% 80,450.37% 449.18% 17,993.39% 735.42% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.96) $0.14 ($1.91) ($1.55) ($1.64)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 25.89M 37.25M 38.39M 39.35M 40.53M
Adjusted Diluted Earnings per Share		 $0.00 ($1.96) $0.14 ($1.91) ($1.55) ($1.64)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 25.89M 38.17M 38.39M 39.35M 40.53M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 37.19M 38.34M 38.92M 40.34M 40.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -32 -2.83 -59 -39 -46
Normalized NOPAT Margin		 -291.06% -11,811.46% -6.33% -7,324.16% -260.76% 0.00%
Pre Tax Income Margin		 -370.01% -19,082.09% 1.90% -9,541.40% -409.03% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -4.87 -2.11 -117.58 -2,834.68 -1,204.75 -1,343.90
NOPAT to Interest Expense		 -3.90 -1.92 -1,331.40 -2,097.85 -897.72 -968.40
EBIT Less CapEx to Interest Expense		 -4.95 -2.18 -420.21 -3,028.00 -1,221.58 -1,335.75
NOPAT Less CapEx to Interest Expense		 -3.98 -1.99 -1,634.03 -2,291.17 -914.55 -960.25
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -4.24% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Barinthus Biotherapeutics

This table displays calculated financial ratios and metrics derived from Barinthus Biotherapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 38,524,963.00 38,565,272.00 38,921,212.00 39,033,158.00 39,414,722.00 40,228,456.00 40,339,395.00 40,339,395.00 40,718,229.00 40,830,353.00 40,848,893.00
DEI Adjusted Shares Outstanding		 38,524,963.00 38,565,272.00 38,921,212.00 39,033,158.00 39,414,722.00 40,228,456.00 40,339,395.00 40,339,395.00 40,718,229.00 40,830,353.00 40,848,893.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.37 -0.45 -0.40 -0.43 -0.21 -0.51 -0.49 -0.52 -0.36 -0.27 -0.14
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% 0.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00%
EBITDA Growth		 -274.39% 26.28% 22.07% 33.36% 45.85% -14.77% -22.16% -22.07% -95.30% 46.20% 72.34%
EBIT Growth		 -328.84% 23.97% 19.71% 31.00% 41.31% -13.60% -23.92% -23.27% -72.66% 45.54% 70.89%
NOPAT Growth		 -243.02% 20.58% 21.27% 30.57% 41.76% -17.02% -21.79% -27.55% -60.62% 50.56% 70.51%
Net Income Growth		 -271.63% 18.30% 14.83% 28.88% 42.39% -19.09% -26.66% -24.69% -79.25% 46.08% 71.85%
EPS Growth		 -268.18% 21.43% 16.67% 30.65% 43.24% -15.91% -22.50% -20.93% -71.43% 47.06% 71.43%
Operating Cash Flow Growth		 -194.17% -72.82% -272.46% 29.20% -62.61% 166.76% -26.05% -50.83% 41.06% -132.42% 77.41%
Free Cash Flow Firm Growth		 90.86% 63.69% -145.71% -1,625.68% -877.61% 207.11% 208.31% 213.83% 238.30% -33.32% -9.03%
Invested Capital Growth		 -19.87% -8.01% -0.46% -12.19% 51.18% -60.51% -64.29% -63.39% -83.60% -86.24% -104.74%
Revenue Q/Q Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 44.44% -28.38% 13.63% -8.17% 54.86% -172.11% 8.07% -8.09% 27.78% 25.04% 52.73%
EBIT Q/Q Growth		 41.49% -25.31% 12.61% -7.68% 50.23% -142.55% 4.67% -7.12% 30.29% 23.50% 49.04%
NOPAT Q/Q Growth		 38.85% -24.11% 15.38% -8.11% 48.70% -149.36% 11.93% -13.22% 35.41% 23.24% 47.47%
Net Income Q/Q Growth		 40.77% -22.54% 10.24% -9.17% 52.02% -153.30% 4.53% -7.47% 31.03% 23.80% 50.16%
EPS Q/Q Growth		 40.32% -18.92% 9.09% -7.50% 51.16% -142.86% 3.92% -6.12% 30.77% 25.00% 48.15%
Operating Cash Flow Q/Q Growth		 34.00% -75.17% 39.69% -1.56% -51.57% 171.91% -213.88% -21.52% 40.77% 60.45% 20.65%
Free Cash Flow Firm Q/Q Growth		 -488.81% -300.10% -15.51% 36.58% -233.56% 143.84% 16.80% -33.35% 305.27% -78.86% 59.35%
Invested Capital Q/Q Growth		 -20.57% 27.23% -6.37% -7.20% 36.76% -66.76% -15.34% -4.86% -38.75% -72.11% -129.14%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -48.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -62.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -58.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -54.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 95.90% 95.47% 99.76% 99.96% 99.96% 100.01% 99.89% 99.88% 99.52% 99.49% 99.71%
Interest Burden Percent		 98.73% 96.98% 95.32% 96.45% 92.98% 97.05% 97.31% 97.64% 96.96% 96.60% 94.28%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -14.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -13.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 10.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% -34.13% -4.58% 0.00% 0.00% 0.00% -62.25% -65.02% -57.49%
Cash Return on Invested Capital (CROIC)		 -135.14% -117.00% -131.33% -106.63% -142.72% -65.16% -81.07% -108.64% -42.04% -337.98% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -4.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -3.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% -34.09% -4.57% 0.00% 0.00% 0.00% -62.18% -64.96% -57.43%
Return on Equity Simple (ROE_SIMPLE)		 -39.57% 0.00% -41.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -14 -12 -13 -6.57 -16 -14 -16 -11 -8.10 -4.25
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -43.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.57% -1.96% -2.29% -2.85% -1.17% -3.31% -4.54% -4.66% -4.42% -3.26% -1.53%
Return On Investment Capital (ROIC_SIMPLE)		 - -7.48% -6.88% -8.16% -4.12% -12.58% -12.47% -15.93% -12.47% -10.90% -6.40%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 89.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 74.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 162.66% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -15 -19 -16 -18 -8.75 -21 -20 -22 -15 -12 -5.89
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -17 -15 -16 -7.27 -20 -18 -20 -14 -11 -5.03
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.61 0.76 0.54 0.35 0.29 0.37 0.34 0.37 0.60 0.39 0.35
Price to Tangible Book Value (P/TBV)		 0.76 0.95 0.68 0.45 0.38 0.45 0.42 0.46 0.73 0.48 0.44
Price to Revenue (P/Rev)		 16.40 177.44 277.34 0.00 3.13 3.25 2.62 2.51 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.82 -0.78 -0.79 -0.78 -0.75 -0.80 -0.80 -0.79 -0.75 -0.90 -0.92
Leverage Ratio		 1.15 1.13 1.14 1.16 1.18 1.18 1.19 1.22 1.22 1.26 1.29
Compound Leverage Factor		 1.13 1.09 1.08 1.12 1.10 1.15 1.16 1.19 1.18 1.22 1.21
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.10% 0.11% 0.11% 0.11% 0.10% 0.08% 0.09% 0.10% 0.11% 0.11% 0.12%
Common Equity to Total Capital		 99.90% 99.89% 99.89% 99.89% 99.90% 99.92% 99.91% 99.90% 99.89% 99.89% 99.88%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 1.72 2.47 1.19 -0.04 0.04 -0.63 -1.18 -1.80 -2.14 -3.18 -3.58
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.11% 0.10% 0.00% 0.00% 0.00% 0.11% 0.09% 0.10%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.21 12.45 11.15 8.46 8.93 8.03 9.18 7.89 8.04 7.77 6.05
Quick Ratio		 8.63 11.28 0.00 0.00 0.00 7.07 8.28 6.78 6.88 7.03 5.49
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.52 -10 -12 -7.38 -25 11 13 8.41 34 7.20 11
Operating Cash Flow to CapEx		 -31,086.11% 0.00% -3,838.31% -6,253.13% -15,963.16% 4,707.19% -298,040.00% -56,590.63% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -359.93 -1,440.09 -970.32 -615.35 -1,448.88 899.75 970.08 700.43 2,620.29 553.81 882.50
Operating Cash Flow to Interest Expense		 -1,598.71 -2,800.43 -985.17 -1,000.50 -1,070.47 1,090.50 -1,146.31 -1,509.08 -825.08 -326.31 -258.92
Operating Cash Flow Less CapEx to Interest Expense		 -1,603.86 -2,778.57 -1,010.83 -1,016.50 -1,077.18 1,067.33 -1,146.69 -1,511.75 -825.08 -326.15 -254.69
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.03 0.00 0.00 0.00 0.07 0.08 0.09 0.09 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.76 0.08 0.03 0.00 1.30 1.56 1.69 1.93 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 35 45 42 39 53 18 15 14 8.75 2.44 -0.71
Invested Capital Turnover		 0.18 0.02 0.01 0.00 0.34 0.48 0.52 0.56 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -8.75 -3.91 -0.20 -5.42 18 -27 -27 -25 -45 -15 -16
Enterprise Value (EV)		 -41 0.43 -37 -63 -59 -64 -61 -50 -25 -43 -44
Market Capitalization		 119 142 93 55 47 49 39 38 51 29 23
Book Value per Share		 $5.07 $4.84 $4.41 $4.01 $4.04 $3.23 $2.86 $2.54 $2.07 $1.82 $1.63
Tangible Book Value per Share		 $4.08 $3.88 $3.48 $3.10 $3.15 $2.69 $2.34 $2.03 $1.71 $1.47 $1.29
Total Capital		 196 187 172 157 159 130 116 102 85 74 66
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -160 -142 -130 -118 -106 -112 -101 -88 -76 -72 -67
Capital Expenditures (CapEx)		 0.04 -0.15 0.31 0.19 0.11 0.28 0.01 0.03 0.00 -0.00 -0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.81 2.22 0.33 -1.48 13 -2.32 -2.67 -0.10 0.31 -4.08 -6.53
Debt-free Net Working Capital (DFNWC)		 152 144 130 116 120 110 98 88 76 68 61
Net Working Capital (NWC)		 152 144 130 116 120 110 98 88 76 68 61
Net Nonoperating Expense (NNE)		 2.84 3.30 3.68 4.14 1.56 4.22 5.24 4.80 4.02 3.01 1.28
Net Nonoperating Obligations (NNO)		 -160 -142 -130 -118 -106 -112 -101 -88 -76 -72 -67
Total Depreciation and Amortization (D&A)		 1.47 1.44 1.43 1.47 1.48 1.43 2.03 2.00 0.90 0.91 0.86
Debt-free, Cash-free Net Working Capital to Revenue		 -107.63% 276.43% 97.31% 0.00% 90.05% -15.47% -17.86% -0.63% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 2,100.79% 17,993.39% 39,010.78% 0.00% 798.86% 735.42% 654.06% 585.80% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 2,100.79% 17,993.39% 39,010.78% 0.00% 798.86% 735.42% 654.06% 585.80% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.37) ($0.44) ($0.40) ($0.43) ($0.21) ($0.51) ($0.49) ($0.52) ($0.36) ($0.27) ($0.14)
Adjusted Weighted Average Basic Shares Outstanding		 38.53M 38.39M 38.77M 39.04M 39.42M 39.35M 40.27M 40.34M 40.66M 40.53M 40.85M
Adjusted Diluted Earnings per Share		 ($0.37) ($0.44) ($0.40) ($0.43) ($0.21) ($0.51) ($0.49) ($0.52) ($0.36) ($0.27) ($0.14)
Adjusted Weighted Average Diluted Shares Outstanding		 38.53M 38.39M 38.77M 39.04M 39.42M 39.35M 40.27M 40.34M 40.66M 40.53M 40.85M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 38.57M 38.92M 39.03M 39.41M 40.23M 40.34M 40.34M 40.72M 40.83M 40.85M 40.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -14 -12 -13 -6.57 -16 -14 -16 -7.28 -8.10 -4.25
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -43.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -54.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -2,128.86 -2,667.71 -1,360.00 -1,464.42 -514.47 -1,767.75 -1,555.62 -1,805.17 -1,161.62 -888.69 -452.85
NOPAT to Interest Expense		 -1,610.50 -1,998.80 -986.65 -1,066.68 -386.24 -1,364.42 -1,109.23 -1,360.57 -811.25 -622.73 -327.12
EBIT Less CapEx to Interest Expense		 -2,134.00 -2,645.86 -1,385.67 -1,480.42 -521.18 -1,790.92 -1,556.00 -1,807.83 -1,161.62 -888.54 -448.62
NOPAT Less CapEx to Interest Expense		 -1,615.64 -1,976.94 -1,012.32 -1,082.68 -392.94 -1,387.58 -1,109.62 -1,363.23 -811.25 -622.58 -322.88
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Barinthus Biotherapeutics (NASDAQ: BRNS) continues to look like a development-stage biotech with a strong cash position, but one that is still burning cash and not yet generating revenue. The latest quarter shows the company remains well funded for now, though spending and losses remain elevated.

  • Cash remains substantial. BRNS ended Q1 2026 with $65.9 million in cash and equivalents, plus $1.3 million in restricted cash, giving it a solid near-term liquidity base.
  • Current assets comfortably exceed current liabilities. Total current assets were $72.7 million versus total current liabilities of $12.0 million, suggesting the company can meet short-term obligations.
  • Net cash used in operations improved versus late 2025. Operating cash outflow was $3.4 million in Q1 2026, narrower than the $4.2 million outflow in Q4 2025 and much better than the larger burn seen in earlier periods.
  • R&D spending declined sharply year over year in the latest quarter. Research and development expense fell to $3.6 million from $5.4 million in Q3 2025 and $8.3 million in Q1 2025, which may reflect tighter spending or a shift in development activity.
  • SG&A also came down materially. Selling, general and administrative expense was $2.5 million in Q1 2026, down from $7.6 million in Q4 2025 and $12.6 million in Q1 2025.
  • There is still no revenue. The company reported $0 in revenue in Q1 2026, consistent with the prior several quarters, so profitability remains dependent on future clinical or partnership success.
  • The balance sheet is still equity-heavy. Total equity stood at $66.4 million versus total liabilities of $25.7 million, but retained earnings remain deeply negative at -$309.6 million, reflecting years of accumulated losses.
  • Cash declined in the quarter. Cash and equivalents fell from $74.3 million at the end of Q3 2025 to $65.9 million at the end of Q1 2026.
  • The company is still unprofitable. Q1 2026 net loss was $5.5 million, or $(0.14) per share, so the business has not yet reached break-even.
  • Exchange-rate effects continue to matter. BRNS reported a $1.4 million negative foreign exchange impact in Q1 2026, which added to the quarterly cash decline.

Looking at the bigger picture, BRNS has dramatically reduced its cash balance over the last four quarters, falling from about $99.1 million in Q1 2025 to $65.9 million in Q1 2026. That still leaves the company with a meaningful runway, but the trend shows ongoing consumption of capital.

Bottom line: Barinthus Biotherapeutics appears financially stable in the near term thanks to its cash cushion and low current debt-like liabilities, but investors should focus on whether the company can convert its pipeline into revenue before cash burn becomes a larger concern.

07/31/26 08:17 PM ETAI Generated. May Contain Errors.

Barinthus Biotherapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Barinthus Biotherapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Barinthus Biotherapeutics' net income appears to be on an upward trend, with a most recent value of -$66.46 million in 2025, rising from -$17.93 million in 2020. The previous period was -$61.18 million in 2024. View Barinthus Biotherapeutics' forecast to see where analysts expect Barinthus Biotherapeutics to go next.

Barinthus Biotherapeutics' total operating income in 2025 was -$70.56 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $70.56 million

Over the last 5 years, Barinthus Biotherapeutics' total revenue changed from $4.82 million in 2020 to $0.00 in 2025, a change of -100.0%.

Barinthus Biotherapeutics' total liabilities were at $23.88 million at the end of 2025, a 20.9% decrease from 2024, and a 55.6% decrease since 2020.

In the past 5 years, Barinthus Biotherapeutics' cash and equivalents has ranged from $43.27 million in 2020 to $214.05 million in 2021, and is currently $70.46 million as of their latest financial filing in 2025.

Over the last 5 years, Barinthus Biotherapeutics' book value per share changed from -4.72 in 2020 to 1.82 in 2025, a change of -138.5%.


Related Companies

Financial statements for NASDAQ:BRNS last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
“The unseen winner of the AI race” is not SpaceX
Marc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...
Chaikin Analytics | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...
SmartAsset | Sponsoredtc pixel